Two peptides developed behind the Iron Curtain now occupy a prominent position in contemporary nootropic research. Selank, a synthetic heptapeptide with GABAergic anxiolytic activity, and Semax, an ACTH-derived fragment that upregulates brain-derived neurotrophic factor, were both created at the Institute of Molecular Genetics in Moscow — yet their mechanisms are distinct enough that researchers frequently study them in tandem. This deep dive covers the origins, pharmacology, and preclinical research profiles of both compounds, and explains why they have attracted sustained scientific interest since the 1980s.
Modern peptide nootropic research owes a substantial debt to Soviet neuroscience. From the late 1970s onward, researchers at the Institute of Molecular Genetics (IMG) in Moscow pursued a systematic programme of neuropeptide synthesis, seeking pharmacological tools that could modulate cognition and stress without the side-effect profile of classical benzodiazepines or stimulants. The institutional context mattered: the Soviet military and space programme had a direct interest in agents that could sustain cognitive performance under high-stress conditions, and the IMG was given significant resources to pursue that goal.
Semax emerged first, developed during the 1980s as a synthetic analogue of the adrenocorticotropic hormone (ACTH) fragment spanning positions 4 through 7, extended with a Pro-Gly-Pro C-terminal tripeptide to improve metabolic stability. The parent ACTH(4-7) sequence — Met-Glu-His-Phe — had been identified as possessing cognitive-modulating activity in earlier animal research, but its rapid enzymatic degradation in biological fluids made it impractical as a research tool. The Pro-Gly-Pro extension substantially prolonged the effective half-life without altering the core pharmacophore.
Selank followed in the 1990s, synthesised as a heptapeptide analogue of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by the spleen and known for its immunomodulatory properties. The research team at the IMG extended tuftsin with a Trp-Pro-Arg C-terminal addition, yielding the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The structural modification preserved tuftsin’s immunomodulatory character while conferring a new and clinically interesting anxiolytic activity profile.
Both compounds were approved for clinical use in Russia — Semax as a nasal spray for stroke management and cognitive decline, Selank as a prescription anxiolytic — giving them an unusually detailed human-use record by the standards of nootropic peptides. Outside Russia, however, they remain strictly in the preclinical research domain.
Selank’s primary research interest lies in its anxiolytic activity, which operates through a mechanism distinct from classical benzodiazepines. In vitro and in vivo preclinical data indicate that Selank modulates GABA-A receptor function — enhancing the affinity of GABA for its receptor complex — rather than binding directly at the benzodiazepine allosteric site. This distinction is pharmacologically significant: benzodiazepines produce tolerance partly because chronic allosteric site occupancy leads to receptor internalisation and subunit remodelling. Selank’s indirect modulation of GABA-A activity, if borne out in further mechanistic research, may represent a qualitatively different interaction with the GABAergic system.
Preclinical studies in rodent models have reported several findings relevant to stress and anxiety research:
Researchers studying stress-resilience mechanisms consider Selank a useful experimental tool precisely because its multi-target profile — GABAergic, serotonergic, and immunological — allows investigation of the crosstalk between these systems in anxiety-like behaviour.
For researchers sourcing material, Biohacker’s Selank capsules are produced at 99%+ HPLC purity with batch-level certificates of analysis available at the COA portal.
Where Selank is primarily studied for its anxiolytic and stress-modulating properties, Semax occupies a different research niche: cognitive activation and neuroprotection. Its most replicated and mechanistically interesting finding is upregulation of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex of rodent models.
BDNF is a member of the neurotrophin family that plays a central role in synaptic plasticity, long-term potentiation (LTP), and the survival of existing neurons. BDNF signalling through the TrkB receptor is widely regarded as a key mediator of learning and memory consolidation; its downregulation is implicated in depression, cognitive ageing, and neurodegeneration. Compounds that reliably upregulate BDNF expression are therefore of substantial research interest.
In rodent studies, Semax administration has been associated with:
Biohacker’s Semax capsules are formulated with enteric protection to address the oral bioavailability challenges inherent in peptide compounds (see below). Each batch is independently third-party tested; COAs are published at biohacker.dev-up.click/coas/.
The two peptides are frequently discussed together because their research profiles are complementary rather than redundant. The table below summarises the key distinguishing characteristics.
| Parameter | Selank | Semax |
|---|---|---|
| Origin | Synthetic analogue of tuftsin; developed at Institute of Molecular Genetics, Moscow, 1990s | Synthetic analogue of ACTH(4–7); developed at Institute of Molecular Genetics, Moscow, 1980s |
| Peptide class | Heptapeptide (7 amino acids); tuftsin derivative | Heptapeptide (7 amino acids); ACTH fragment derivative |
| Primary mechanism | Positive modulation of GABA-A receptor; serotonin transporter regulation | BDNF and NGF upregulation via TrkB pathway; dopaminergic modulation |
| Primary research domain | Anxiety, stress biomarkers, HPA axis reactivity, immunomodulation | Cognitive enhancement, synaptic plasticity, neuroprotection, stroke models |
| Administration history (clinical) | Intranasal; registered as prescription anxiolytic in Russia | Intranasal; registered for stroke and cognitive decline in Russia |
| Oral capsule considerations | Requires enteric protection to resist gastric acid degradation | Requires enteric protection to resist gastric acid degradation |
| Complementary role in research | Anxiolytic/stress regulation arm | Cognitive activation/neuroplasticity arm |
The logic behind studying them in combination is straightforward: anxiety and cognitive impairment frequently co-occur, and the mechanisms underlying them — HPA dysregulation, reduced GABAergic tone, diminished BDNF signalling — interact bidirectionally. A research protocol that modulates both axes simultaneously may yield more ecologically valid data on stress-cognition interactions than either compound alone.
Both Selank and Semax were originally developed for intranasal administration, which bypasses first-pass hepatic metabolism and avoids the gastric acid environment that degrades peptide bonds. The shift to oral capsule format — now the preferred delivery vehicle for research applications outside clinical settings — introduces a formulation challenge: unprotected peptides are susceptible to rapid hydrolysis by gastric acid (pH 1.5–3.5) and pepsin before they reach the small intestine.
Enteric coating addresses this by using pH-sensitive polymers (typically cellulose acetate phthalate or methacrylic acid copolymers) that remain intact at low gastric pH but dissolve at the higher pH (approximately 5.5–7.0) of the duodenum and jejunum. This shifts peptide release to the small intestinal environment, where the pH is more permissive and the enzymatic milieu less destructive. Absorption then depends on transcellular and paracellular transport mechanisms, and absolute bioavailability remains lower than intranasal delivery — a variable that researchers must account for in dose-response experimental design.
Biohacker’s formulations for both Selank and Semax incorporate enteric protection and are produced at 99%+ HPLC purity. For researchers interested in related neuroprotective peptides, Pinealon — a tripeptide (Ala-Glu-Asp) derived from pineal gland extracts with documented neuroprotective activity in preclinical models — is also available, and is sometimes studied alongside Selank and Semax in multi-peptide neuroprotection protocols. The full catalogue is accessible at the Biohacker shop.
Evaluating the credibility of research on any peptide compound requires situating it within its regulatory and publication history. For Selank and Semax, two features are especially relevant.
Russian clinical registration: Both compounds hold clinical approvals from the Russian Ministry of Health — Semax (nasal spray, 0.1% solution) for ischaemic stroke and memory impairment, and Selank (nasal spray) as an anxiolytic. Clinical registration in a major regulatory jurisdiction is a higher evidentiary bar than preclinical study alone. Published clinical trial data — primarily in Russian-language journals, though some translated into English — include controlled studies with documented adverse event profiles and efficacy endpoints. This does not constitute FDA or EMA approval and should not be interpreted as such, but it does provide a human safety and tolerability dataset that most research peptides lack entirely.
Peer-reviewed publication record: A search of PubMed using the terms “Selank” and “Semax” returns over 80 and 120 indexed publications respectively (as of 2025), spanning mechanistic biochemistry, rodent behavioural pharmacology, electrophysiology, and clinical studies. Key research groups include teams at the IMG itself (notably the laboratory of Nikolai Myasoedov, who led much of the original Semax development) and independent groups at Russian and European academic centres. The existence of a multi-decade, multi-laboratory publication record distinguishes these compounds from many nootropics whose research base consists primarily of single-group or unpublished findings.
Researchers using these compounds should nonetheless apply standard critical appraisal to individual studies. Sample sizes in many rodent studies are modest, and the translation of preclinical findings to human biology remains unconfirmed for the majority of reported endpoints.
Of the two compounds, Selank has the more extensive published literature on anxiolytic endpoints. Researchers studying GABAergic mechanisms, stress biomarker normalisation, and immunomodulation have used Selank as the primary study compound across multiple preclinical models. Its documented ability to regulate interleukin expression alongside its central GABA-A activity gives it a multi-system research profile that extends beyond pure anxiolysis.
The most fundamental difference is mechanistic: Selank’s primary documented activity involves positive modulation of the GABA-A receptor complex and serotonin transporter regulation, placing it in the anxiolytic/stress-modulation research category. Semax upregulates BDNF and NGF expression, activating neurotrophic signalling pathways associated with synaptic plasticity and neuroprotection. In practical research terms, Selank is more commonly used to study anxiety and HPA axis reactivity, while Semax is used to study memory consolidation, cognitive performance, and neuronal resilience.
Intranasal delivery allows peptides to partially bypass the blood-brain barrier via olfactory epithelium transport and avoids gastric acid degradation entirely. Both peptides were developed for this route in the clinical setting. Oral capsule formulations use enteric-coated technology to protect the peptide through the gastric environment, releasing it in the small intestine. Absolute bioavailability via the oral route is lower and less predictable than intranasal delivery, which is a variable researchers should factor into experimental design when comparing findings across delivery routes.
Preclinical rationale for studying the two compounds together comes from the bidirectional relationship between stress and cognition. Chronic stress suppresses BDNF expression and reduces hippocampal neuroplasticity — the very pathway Semax is hypothesised to activate. Simultaneously, cognitive overload can drive HPA axis reactivity — the pathway Selank is hypothesised to attenuate. Researchers interested in stress-cognition interactions therefore have a mechanistic basis for investigating both simultaneously. Published data on combination protocols remain limited, and direct interaction studies are an active area of preclinical inquiry.
No. Both compounds hold clinical registration in Russia for specific indications, but neither holds approval from the FDA (United States), EMA (European Union), or equivalent regulatory bodies in most countries. Outside Russia, they are available exclusively as research compounds for use in preclinical laboratory contexts. They are not approved for human consumption, therapeutic use, or dietary supplement applications in most jurisdictions. Researchers should consult applicable national regulations before procurement or use.
HPLC purity of 99%+ is the accepted benchmark for research-grade peptides. HPLC (high-performance liquid chromatography) quantifies the target peptide as a percentage of total UV-absorbing material; a result below 95% indicates the presence of synthetic byproducts, truncated sequences, or other impurities that could confound experimental results. Third-party testing — where an independent laboratory, not the manufacturer, performs the HPLC analysis — provides the strongest quality assurance. Batch-level certificates of analysis (COAs) allow researchers to verify purity for the specific lot they are using. Biohacker publishes batch-level COAs for all compounds, including Selank and Semax, at biohacker.dev-up.click/coas/.
Pinealon is a distinct compound — a tripeptide (Ala-Glu-Asp) derived from pineal gland tissue — with a neuroprotective research profile that partly overlaps with Semax. Like Semax, it has been studied in ischaemia and neurodegeneration models, where it has demonstrated antioxidant activity and support for neuronal survival. It does not share the GABAergic mechanism of Selank or the ACTH-derived structure of Semax. Researchers running multi-peptide neuroprotection protocols sometimes include Pinealon alongside Semax to investigate additive or synergistic effects on neuronal resilience endpoints.
Published preclinical studies for both compounds predominantly used intranasal or intraperitoneal delivery routes with established dose ranges. Translating these to oral capsule protocols requires accounting for lower and more variable bioavailability. In the absence of published oral bioavailability data for enteric-coated formulations, researchers typically begin with conservative dose escalation protocols and include appropriate vehicle controls. Pilot pharmacokinetic characterisation — measuring plasma peptide levels at multiple time points — is advisable before committing to a large experimental cohort with a fixed oral dose.
Research Disclaimer: All information presented in this article relates exclusively to preclinical research findings. Selank and Semax are not approved by the FDA, EMA, or equivalent regulatory bodies outside Russia for human therapeutic use. The compounds discussed are available as research-grade materials for use in laboratory settings only. Nothing in this article constitutes medical advice, a therapeutic claim, or an endorsement of human self-administration. Researchers are responsible for complying with all applicable national and institutional regulations governing the procurement, handling, and use of research peptides. Biohacker products are sold strictly for research purposes.
For the oral delivery science behind capsule-format neuropeptides, see Peptides Without Needles. For a broader orientation to the research peptide catalogue, see the Beginner’s Guide to Research Peptides.
Biohacker’s research compounds are independently authenticated by accredited third-party laboratories — every batch is tested by specialists in analytical chemistry before it ships. Our team’s compound sourcing standards require a minimum 99% HPLC purity floor, ESI-MS mass confirmation, and endotoxin compliance to USP <85> on every lot. Average purity across the catalogue is 99.67%. These are not supplier-claimed figures — they are independently verified results, published batch-by-batch at biohacker.dev-up.click/coas/.
All Biohacker compounds are for laboratory and scientific research use only. They are not intended for human or veterinary use, clinical application, or diagnostic purposes.